Friday December 15, 1:39 pm Eastern Time
Press Release
SOURCE: Cambridge NeuroScience, Inc.
Cambridge NeuroScience Shareholders Approve Merger With CeNeS Pharmaceuticals PLC
NORWOOD, Mass., Dec. 15 /PRNewswire/ -- Cambridge NeuroScience, Inc. (OTC Bulletin Board: CNSI - news) announced that its shareholders voted to approve the proposed merger with CeNeS Pharmaceuticals at a special meeting today. The merger was first announced on May 23, 2000. Shareholders of CeNeS had voted to approve the merger on December 8, 2000. The merger is expected to be completed on December 18, 2000, subject to completion of closing procedures and conditions.
This statement in this press release regarding the anticipated closing date of the proposed merger is a forward-looking statement. There are certain important factors that could cause this forward-looking statement to be materially inaccurate. These factors include, without limitation, the failure of the Company and CeNeS to comply with certain closing requirements and conditions of the merger. The reader should not rely on any forward-looking statements, and CNSI does not undertake any obligation to update forward- looking statements whether as a result of new information, future events or otherwise. Readers should evaluate any statements in light of the Risk Factors section in CNSI's Annual Report on Form 10-K and the definitive proxy statement/prospectus filed with the SEC by CeNeS.
Contacts:
Robert N. McBurney Glenn A. Shane
President and CEO Controller and Treasurer
Cambridge NeuroScience, Inc. Cambridge NeuroScience, Inc.
(781) 255-6700 ext. 114 (781) 255-6700 ext. 110 |
